Transcat (TRNS) Q4 2025 Earnings Call May 20, 2025 11:00 AM ET Company Participants Thomas Barbato - CFOLee Rudow - President, CEO and Director Conference Call Participants Greg Palm - Senior Research AnalystEdward Jackson - MD & Senior Research AnalystScott Buck - Managing Director & Senior Technology Analyst Operator Greetings, welcome to Transcat Inc. Fourth Quarter and Full Fiscal Year twenty twenty five Financial Results Call. As a reminder, this conference is being recorded. It is now my pleasure to i ...

Invivyd (IVVD) FY 2025 Conference May 20, 2025 11:00 AM ET Speaker0 Not ready. Okay. Hello, everyone, and welcome to the third annual, HC Wainwright BioConnect Conference. I'm Patrick Trucchio, a senior health parent at HC Wainwright. It's my pleasure to, introduce you to the management of InVivid. I'm Katie Falzoni, senior vice president of finance and Robert Allen, CSO. So first, I think it'd be good to start out with, some background on Invivid platform and on the validation of this antibody platform. Sp ...

Financial Data and Key Metrics Changes - Fiscal year 2025 consolidated revenue increased by 7% to $278.4 million, driven by consistent demand for services and products [5][12] - Service revenue grew by 7% to $181.4 million, while distribution revenue increased by 8% to $97 million [6][12] - Operating cash flow reached a record $38.6 million, an 18% year-over-year increase [6] - Q4 net income decreased to $4.5 million from $6.9 million in the prior year, with diluted earnings per share dropping to $0.48 from $0.77 [15] - Full year net income increased by 6% to $14.5 million [15] Business Line Data and Key Metrics Changes - Calibration Services achieved double-digit revenue growth of 11% in Q4, with organic growth in the high single-digit range [7][11] - Distribution revenue in Q4 grew by 4%, driven by growth in the rental channel [8][12] - Service gross margin expanded by 50 basis points to 36.2% in Q4, while distribution gross margin decreased by 30 basis points to 28.2% [13][14] Market Data and Key Metrics Changes - The rental platform continues to show growth, contributing to the overall performance of the distribution segment [8][12] - The company noted that barriers to entry in the service market have defended its unique value proposition and strong brand [10] Company Strategy and Development Direction - The acquisition of Martin Calibration is seen as highly synergistic, expanding geographic reach and capabilities [6][7] - The company aims to leverage its strengths in leadership and culture to execute its strategy and vision for future growth [20] - Management expressed confidence in the resilience of the calibration services channel, benefiting from recurring revenue streams in regulated markets [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged short-term volatility but expressed confidence in the company's ability to return to high single-digit growth levels as macro trends normalize [19][29] - The leadership team is focused on improving sales and operational processes, with expectations for stabilization and growth in the Solutions business [20][50] - Management remains optimistic about the future, citing a strong pipeline for strategic acquisitions and ongoing improvements in service delivery [19][43] Other Important Information - The company plans to file its 10-K on May 27 [18] - Operating free cash flow improved by 31% to $25.4 million [16] Q&A Session Summary Question: Can you discuss the cadence of business performance in Q4? - Management characterized Q4 as solid, with pent-up demand contributing to high single-digit organic growth [25][26] Question: Were there any significant opportunities in the service business? - Management confirmed a healthy pipeline of new opportunities and new wins expected to contribute to momentum in the latter half of the year [28] Question: How is the distribution segment responding to tariff announcements? - Management noted that distribution has held up well, with current orders possibly influenced by customers trying to get ahead of tariffs [30][31] Question: What are the levers for expense control? - Management highlighted delayed hires and good cost management as key factors, with expectations for some nominal increases in expenses moving forward [37][38] Question: How is the Solutions business progressing? - Management reported steady progress in integrating the Solutions channel into the overall service platform, with expectations for improved results [50] Question: What is the current status of automation efforts? - Management indicated that automation efforts are ongoing, with significant progress made, but still more work to be done [54][56] Question: How does the company view the rental market in a challenging macro environment? - Management expects rental demand to grow in line with historical trends, particularly as uncertainty persists [66][68]

Beyond Meat (BYND) FY 2025 Annual General Meeting May 20, 2025 11:00 AM ET Speaker0 Good morning. It is now 8AM Pacific Time and I would like to call the meeting to order. I'm Seth Goldman, Chair of the Board of Directors of Beyond Meat Inc. And it is my privilege to welcome you to our twenty twenty five Annual Meeting of Stockholders. Thank you for joining us. We believe that holding the Annual Meeting virtually helps expand access, facilitate stockholder attendance, and reduce costs and the environmental ...

Financial Data and Key Metrics Changes - Total revenues for the second quarter were $686 million, closer to the low end of guidance, primarily due to a mix of deliveries with higher-priced home deliveries slipping into future quarters [7] - Adjusted gross margin was 17.3%, just below the low end of guidance, impacted by increased incentives which rose to 10.5% [7][8] - Adjusted EBITDA was $61 million, slightly above the high end of guidance, while adjusted pretax income was $29 million, near the high end of guidance [10] - Year-over-year total revenues declined despite flat deliveries, primarily due to lower average sales prices [11] Business Line Data and Key Metrics Changes - Contracts for the second quarter, including domestic unconsolidated joint ventures, decreased by 7% year-over-year, with significant monthly sales volatility observed [13] - The company reported 11.2 contracts per community, which is higher than the quarterly average since 2008, despite a year-over-year decline in contracts per community [14][15] - The percentage of home buyers utilizing mortgage rate buy downs was 75%, indicating continued reliance on these incentives to combat affordability [17] Market Data and Key Metrics Changes - The company experienced a 12% increase in the total number of open for sale communities year-over-year, ending the quarter with 148 communities [29] - Controlled lots increased by 15% year-over-year, equating to a 7.7-year supply of controlled lots [30] - The company noted that 60.3% of communities with price increases were in better-performing markets such as Delaware, Maryland, and Virginia [22] Company Strategy and Development Direction - The company is focusing on pace over price, resulting in an above-average number of contracts per community compared to peers, despite a challenging sales environment [16] - A strategic decision was made to burn through less profitable land parcels at lower gross margins to clear the way for recent land acquisitions that meet target return metrics [26] - The company is actively engaging with land sellers to find mutually beneficial solutions in a slow market [26] Management's Comments on Operating Environment and Future Outlook - Management expressed satisfaction with the quarter's performance given the difficult environment, while remaining vigilant about economic uncertainties [49] - The company expects to return to more favorable performance metrics as it replaces certain land positions with newer acquisitions that meet return targets [26] - Guidance for the next quarter assumes no adverse changes in current market conditions, with total revenues expected between $750 million and $850 million [42] Other Important Information - The company ended the quarter with $2 billion in liquidity, within its targeted range, and has made significant progress in reducing debt and improving its balance sheet [38][40] - The company signed a memorandum of understanding with the Ministry of Housing in Saudi Arabia to expand activities and partnerships in the region [27] Q&A Session Summary Question: Have you seen lower land prices on recent acquisitions? - Management indicated that land sellers are slow to adjust prices, but they are finding opportunities to replenish land supply at better returns [56] Question: What markets are yielding better results with land sellers? - Management mentioned markets such as Delaware, Virginia, Southeast Coastal Charleston, New Jersey, and Maryland as currently yielding better results [57] Question: What is the current incentive structure? - The company utilizes a mix of mortgage rate buy downs, price reductions, and other incentives depending on the delivery timeline of homes [63] Question: Is the focus still on spec building? - Management confirmed that the strategy remains focused on quick move-in homes, which allows for affordable mortgage rate buy downs [64] Question: How long will it take to clear older vintage land? - Management noted that the timeline varies by geography, with some areas already cleared out while others may take two to three years [70] Question: What are the expectations for construction costs in the back half of the year? - Management expressed optimism about maintaining or slightly reducing construction costs, barring any significant increases in lumber prices [77]

Anixa Biosciences (ANIX) FY 2025 Conference May 20, 2025 11:00 AM ET Speaker0 Alright. For this session, we'll have a presentation, by Anixa Biosciences. Anixa is a clinical stage immuno oncology company with a pipeline of candidates targeting breast cancer and ovarian cancer. Presenting for the company is Mr. Mike Catalani, President, Chief Operating Officer and Chief Financial Officer of of Adnexa. Mike? Speaker1 Thanks, Yi. Thanks, everybody, for being here. And, for those of you listening, webcast now o ...

Financial Data and Key Metrics Changes - The company finished the first quarter with just under $30 million in cash, with a projected cash runway extending into the first quarter of 2027, indicating a strong financial position for a small company in the current market [51]. Business Line Data and Key Metrics Changes - NXP-800 is currently in a Phase Ib program targeting aggressive subsets of ovarian cancer, with early data showing a partial response and stable disease in initial patients, although there were concerns regarding thrombocytopenia [15][17]. - NXP-900 is in a Phase 1a dose escalation, with early indications of safety and significant SRC inhibition, suggesting it may be a best-in-class SRC inhibitor [35][39]. Market Data and Key Metrics Changes - The addressable patient populations for NXP-800 and NXP-900 vary significantly, with potential expansions into larger indications like endometrial cancer if positive signals are observed in ongoing studies [22]. Company Strategy and Development Direction - The company is focused on precision medicine in oncology, aiming to address severe unmet medical needs with targeted therapies [4]. - There is a strategic emphasis on developing NXP-900 as a transformational drug with potential applications across multiple tumor types, leveraging its selective inhibition of SRC kinases [24][28]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming data updates for both NXP-800 and NXP-900, indicating that the next few months could be eventful and potentially transformational for the company [51][53]. - The management team highlighted their extensive experience in successfully bringing drugs to market, which they believe positions the company well for future success [6]. Other Important Information - The insider ownership is significant, with co-founders and major shareholders collectively owning about 50-55% of the company, reflecting strong alignment with shareholder interests [51]. - The company has seen consistent insider buying since going public, indicating confidence in the company's future prospects [51]. Q&A Session Summary Question: What is the current status of NXP-800 and NXP-900? - NXP-800 is in a Phase Ib program with encouraging early results, while NXP-900 is completing Phase 1a and preparing to enter Phase 1b soon [51][53].

Financial Data and Key Metrics Changes - The total YUPELRI business has shown strong growth, particularly in the hospital channel, recovering well post-COVID pandemic [2][3] - The company has been able to slightly increase pricing, stabilizing it after previous disruptions [12] Business Line Data and Key Metrics Changes - The hospital business for YUPELRI has been growing unit volume at a faster rate, driven by formulary wins and increased sales representative collaboration with Viatris [4][5] - The company is still in the early stages of growth for YUPELRI, indicating significant potential for future expansion [9] Market Data and Key Metrics Changes - The entry of ensifentrine has not significantly impacted the market share of YUPELRI, as it is generally added to existing therapies rather than replacing them [10][11] - The company is focused on optimizing the channel to improve net pricing and overall fulfillment processes [12] Company Strategy and Development Direction - The company is prioritizing the growth of YUPELRI in the hospital setting before considering adding new products to the sales force [14][15] - Ampreloxetine is viewed as a critical asset for future growth, with a focus on efficient commercialization strategies [30][32] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term potential of YUPELRI and Trelegy, highlighting the challenges of replicating Trelegy's success [33][35] - The company is committed to returning excess capital to shareholders while focusing on the success of YUPELRI and the development of ampreloxetine [38] Other Important Information - The company has a strong cash position with $130 million on the balance sheet and potential milestones from Trelegy and YUPELRI [31] - The development of Ampreloxetine is seen as a unique opportunity to address a significant unmet need in treating MSA patients [19][24] Q&A Session Summary Question: Are you losing patients at the initial script fill or during refills? - Management indicated that they lose patients both at the initial fill and during follow-up with regional pulmonologists [8] Question: How is the enrollment for the Ampreloxetine study progressing? - Management emphasized the importance of selecting the right patients and sites for the study, ensuring quality care throughout the process [26][27] Question: What is the long-term outlook for Trelegy and its royalties? - Management believes that Trelegy will continue to perform well in both asthma and COPD markets, with royalties reverting back to the company in 2029 [35]

Zenvia (ZENV) Q4 2024 Earnings Call May 20, 2025 10:00 AM ET Company Participants Cassio Bobsin Machado - Founder, CEO, Chairman & Interim Chief Sales OfficerShay Chor - CFO Operator REPRESENTATIVE:] Today's conference is being recorded and a replay will be available at the company's IR website, where you can also access today's presentation. At this time, all participants are in listen only mode. After the prepared remarks, there will be a question and answer session. And for the Q and A session, we ask yo ...

Prophase Labs (PRPH) Q1 2025 Earnings Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Media Relations Coordinator & Virtual Events ModeratorTed Karkus - Chairman & CEO Noella Alexander-Young Hello, and good morning, everyone. Welcome to today's presentation. My name is Noella Alexander Young, virtual event moderator here at Renmark Financial Communications. On behalf of our team, we want to thank everyone for joining us today for Prophase Labs First Quarter twenty twenty five Res ...